 The purpose of this study is to determine the safety and efficacy of long-term treatment with alogliptin Nesina in patients with type 2 diabetes mellitus who responded inadequately to diet therapy and exercise therapy alone, or a combination of diet therapy, exercise therapy, and α-glucosidase inhibitor. 